According to filings with the U.S. Securities and Exchange Commission, Pascal Medical is raising up to $3,098,719.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Pascal Medical
Pascal Medical is an emerging medtech company focused on developing advanced hydrogel therapeutics using click chemistry to improve patient care. Its core platform, ClickGel, is described on the companys site as an injectable, biocompatible, and biodegradable gel with broad potential for local delivery of biologics, antibiotics, and tissue sealants. The company presents its work as science-driven and shaped by clinical insight, with a goal of transforming patient lives. Pascal also says it is harnessing click chemistry and materials science to address unmet needs across healthcare. The company appears to position itself as an innovative developer of next-generation synthetic polymer solutions for medical applications.

To learn more, visit https://www.pascalmed.com/

Contact:
Thomas Gardner, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.